当前位置： SCI文献检索 > STROKE期刊下所有文献 > Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage.

Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage.

Abstract：

BACKGROUND AND PURPOSE:Recombinant activated factor VII (rFVIIa) reduces hematoma expansion and improves outcome after intracerebral hemorrhage (ICH), with an apparent increase in nonfatal thromboembolic events (TEs) with higher doses. Despite low incidences of such events in rFVIIa-treated hemophiliacs, the frequency in older patients with more atherosclerosis and immobility has yet to be defined. METHODS:Data were pooled from 3 randomized placebo-controlled studies in patients diagnosed within 3 hours of spontaneous ICH who received a single dose of rFVIIa (5 to 160 microg/kg; n=371) or placebo (n=115). Clinical/laboratory evaluations, lower extremity Doppler studies, and 72-hour CT scans were used to monitor for TEs. Adverse events occurring while hospitalized and serious events occurring through day 90 were carefully reviewed. RESULTS:There was no overall increase in risk of total TEs in rFVIIa-treated patents; however, there were more arterial, but not venous, TEs in the high dose group (120 to 160 microg/kg) compared with placebo (5.4% versus 1.7%; P=0.13). Arterial events occurring within 7 days of drug administration classified as possibly or probably associated with study drug included myocardial ischemia (n=9, 8 were non-ST-segment elevation and non-Q-wave events; 2 of the 9 had sequelae) and ischemic stroke (n=9, 4 of which had likely causes other than rFVIIa). Regression analysis identified high doses (120 to 160 microg/kg) of rFVIIa as the only factor associated with arterial TEs (odds ratio=6.75; P=0.02). CONCLUSIONS:There appears to be a increased risk of arterial TEs associated with higher doses of rFVIIa in ICH patients as compared with placebo. Further studies are underway to identify specific factors associated with these events and to define the dose that maximizes benefit and minimizes risk.

journal_name

Stroke

journal_title

Stroke

authors

Diringer MN,Skolnick BE,Mayer SA,Steiner T,Davis SM,Brun NC,Broderick JP

doi

10.1161/STROKEAHA.107.493601

subject

Has Abstract

pub_date

2008-03-01 00:00:00

pages

850-6

issue

eissn

0039-2499

issn

1524-4628

pii

STROKEAHA.107.493601

journal_volume

pub_type

杂志文章,meta分析

在线工具

Risk of thromboembolic events in controlled trials of rFVIIa in spontaneous intracerebral hemorrhage.